View Financial HealthSiegfried Holding 배당 및 자사주 매입배당 기준 점검 0/6Siegfried Holding 은(는) 현재 수익률이 0.49% 인 배당금 지급 회사입니다.핵심 정보0.5%배당 수익률-0.04%자사주 매입 수익률총 주주 수익률0.5%미래 배당 수익률0.6%배당 성장률7.9%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향10%최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 27Siegfried Holding AG, Annual General Meeting, Apr 14, 2026Siegfried Holding AG, Annual General Meeting, Apr 14, 2026, at 10:00 W. Europe Standard Time.공시 • Feb 21Siegfried Announces Management ChangesSiegfried will consolidate the Chief Operating Officer roles currently split between Drug Substances and Drug Products into one position. In this context, Henrik Krüpper will be stepping down from his responsibilities as Chief Operating Officer Drug Substances to pursue opportunities outside the company, effective March 1, 2026. Stefan Randl has been appointed ad interim Chief Operating Officer Drug Substances in addition to his role as Chief Scientific Officer until a Chief Operating Officer is appointed.공시 • Feb 09Siegfried Holding AG to Report First Half, 2026 Results on Aug 21, 2026Siegfried Holding AG announced that they will report first half, 2026 results on Aug 21, 2026공시 • Jan 28+ 2 more updatesSiegfried Holding AG (SWX:SFZN) entered into a binding agreement to acquire Noramco, Inc. from SK Capital Partners, LP and The Noramco Group.Siegfried Holding AG (SWX:SFZN) entered into a binding agreement to acquire Noramco, Inc. from SK Capital Partners, LP and The Noramco Group on January 27, 2026. Given Siegfried’s strong balance sheet, the acquisition will be financed through existing and new debt instruments. In separate related transactions, Siegfried Holding AG also signed binding agreements to acquire Purisys and Extractas Bioscience. Following the close of the transaction, SK Capital will retain ownership of Halo Pharmaceuticals. The transaction is subject to customary closing conditions and regulatory approvals. The expected completion of the transaction is in late 2026. The valuation of the acquired business is below 10 times Enterprise Value / EBITDA. Jefferies Financial Group Inc., RBC Capital Markets, LLC and Rothschild & Co US Inc. acted as financial advisors for Noramco, Inc. Kirkland & Ellis LLP acted as legal advisor for Noramco. The team of Cravath, Swaine & Moore LLP led by G.J. Ligelis Jr., Daniel J. Cerqueira and Ryan J. Wichtowski, Lauren Angelilli, Eric W. Hilfers, David J. Kappos, Carys J. Webb, Margaret T. Segall, Matthew Morreale, Joyce Law, Brian M. Budnick, Crawford Rundlett and Jesús Saracho acted as legal advisor for Siegfried Holding AG.공시 • Sep 04Siegfried Holding AG to Report Fiscal Year 2025 Results on Feb 20, 2026Siegfried Holding AG announced that they will report fiscal year 2025 results on Feb 20, 2026공시 • Mar 24Siegfried Holding AG, Annual General Meeting, Apr 10, 2025Siegfried Holding AG, Annual General Meeting, Apr 10, 2025, at 10:00 W. Europe Standard Time.공시 • Jan 30Siegfried Holding AG to Report First Half, 2025 Results on Aug 21, 2025Siegfried Holding AG announced that they will report first half, 2025 results on Aug 21, 2025공시 • Aug 22Siegfried Holding AG to Report Fiscal Year 2024 Results on Feb 18, 2025Siegfried Holding AG announced that they will report fiscal year 2024 results on Feb 18, 2025공시 • Aug 20Siegfried Holding AG to Report First Half, 2024 Results on Aug 22, 2024Siegfried Holding AG announced that they will report first half, 2024 results on Aug 22, 2024공시 • Jul 02Siegfried Holding AG (SWX:SFZN) completed the acquisition of early-phase CDMO site in Grafton, Wisconsin from Curia Global, Inc.Siegfried Holding AG (SWX:SFZN) agreed to acquire early-phase CDMO site in Grafton, Wisconsin from Curia Global, Inc. on June 12, 2024. The acquisition is financed from existing funds. the transaction is subject to customary closing conditions and is expected to close by July 1, 2024.Siegfried Holding AG (SWX:SFZN) completed the acquisition of early-phase CDMO site in Grafton, Wisconsin from Curia Global, Inc on july 1, 2024. As part of the acquisition, all projects at the Grafton site have been transferred to Siegfried and the Siegfried Acceleration Hub will continue to fulfill all commitments to its existing customers.공시 • Aug 15+ 1 more updateSiegfried Holding AG to Report Fiscal Year 2023 Results on Feb 20, 2024Siegfried Holding AG announced that they will report fiscal year 2023 results on Feb 20, 2024공시 • May 18Siegfried Announces Executive ChangesSiegfried announces two changes to its Executive Committee: Irene Wosgien, currently serving as Chief Operating Officer Drug Substances (COO DS), will take over the global responsibility as Chief Human Resources Officer (CHRO) from Arnoud Middel who will leave Siegfried end of June 2023. Henrik Krupper, currently CEO of HCS Group, will join Siegfried to become the new COO DS. Irene Wosgien will take over as CHRO on 1 July 2023 while Arnoud Middel will assist her during the transition and will continue to support key HR projects until the end of the year. Henrik Krupper will assume his role on 1 November 2023 at the latest. Until then and starting on 1 July 2023, Marcel Imwinkelried will lead the DS technical operations organization in parallel to his regular role as Chief Operating Officer Drug Products. Both, Irene Wosgien and Henrik Krupper, will serve as members of Siegfried's Executive Committee. Arnoud Middel joined Siegfried in 2011 and since then has successfully built a professional global HR function which has been instrumental to Siegfried's organizational development and strong growth over the years. After 12 years with the company, he decided to leave Siegfried in order to pursue private ventures and prepare them next chapters of his career. Henrik Krupper (52, German citizen) holds a diploma (Dipl.-Ing.) in mechanical engineering with a specialization in process engineering from the Technical University (RWTH) Aachen (Germany). After completing his studies, he started his career at Th. Goldschmidt AG as site excellence and production manager followed by positions with increasing operational and managerial responsibilities at Evonik Industries AG (formerly Degussa AG), City Solar AG, Q-Cells SE and Soltecture GmbH. In 2012, he joined HCS Group, an international specialty chemicals company based in Germany, as Managing Director and Chief Commercial Officer and was appointed to his current role of Chief Executive Officer of the company in 2019.공시 • May 06Siegfried Holding AG (SWX:SFZN) acquired 95% stake in DiNAMIQS from DiNAQOR AG.Siegfried Holding AG (SWX:SFZN) acquired 95% stake in DiNAMIQS from DiNAQOR AG on May 4, 2023.Siegfried Holding AG (SWX:SFZN) completed the acquisition of 95% stake in DiNAMIQS from DiNAQOR AG on May 4, 2023.공시 • Aug 20Siegfried Holding AG to Report Fiscal Year 2022 Results on Feb 22, 2023Siegfried Holding AG announced that they will report fiscal year 2022 results on Feb 22, 2023지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: SGFE.F US 시장에서 주목할만한 배당금을 지급하지 않으므로 지급이 안정적인지 확인할 필요가 없습니다.배당금 증가: SGFE.F US 시장에서 주목할만한 배당금을 지급하지 않으므로 지급액이 증가하는지 확인할 필요가 없습니다.배당 수익률 vs 시장Siegfried Holding 배당 수익률 vs 시장SGFE.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (SGFE.F)0.5%시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Life Sciences)0.7%분석가 예측 (SGFE.F) (최대 3년)0.6%주목할만한 배당금: SGFE.F 의 배당금( 0.49% )은 US 시장에서 배당금 지급자의 하위 25%( 1.4% )와 비교해 주목할 만하지 않습니다.고배당: SGFE.F 의 배당금( 0.49% )은 US 시장에서 배당금 지급자의 상위 25%( 4.18% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: SGFE.F US 시장에서 주목할만한 배당금을 지급하지 않습니다.주주 현금 배당현금 흐름 범위: SGFE.F 배당금을 지급하고 있지만 회사에는 잉여현금흐름이 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/27 13:42종가2026/03/12 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Siegfried Holding AG는 16명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Justin Steven SmithBernsteinPatrick Andrew WoodBofA Global ResearchVineet AgrawalCitigroup Inc13명의 분석가 더 보기
공시 • Mar 27Siegfried Holding AG, Annual General Meeting, Apr 14, 2026Siegfried Holding AG, Annual General Meeting, Apr 14, 2026, at 10:00 W. Europe Standard Time.
공시 • Feb 21Siegfried Announces Management ChangesSiegfried will consolidate the Chief Operating Officer roles currently split between Drug Substances and Drug Products into one position. In this context, Henrik Krüpper will be stepping down from his responsibilities as Chief Operating Officer Drug Substances to pursue opportunities outside the company, effective March 1, 2026. Stefan Randl has been appointed ad interim Chief Operating Officer Drug Substances in addition to his role as Chief Scientific Officer until a Chief Operating Officer is appointed.
공시 • Feb 09Siegfried Holding AG to Report First Half, 2026 Results on Aug 21, 2026Siegfried Holding AG announced that they will report first half, 2026 results on Aug 21, 2026
공시 • Jan 28+ 2 more updatesSiegfried Holding AG (SWX:SFZN) entered into a binding agreement to acquire Noramco, Inc. from SK Capital Partners, LP and The Noramco Group.Siegfried Holding AG (SWX:SFZN) entered into a binding agreement to acquire Noramco, Inc. from SK Capital Partners, LP and The Noramco Group on January 27, 2026. Given Siegfried’s strong balance sheet, the acquisition will be financed through existing and new debt instruments. In separate related transactions, Siegfried Holding AG also signed binding agreements to acquire Purisys and Extractas Bioscience. Following the close of the transaction, SK Capital will retain ownership of Halo Pharmaceuticals. The transaction is subject to customary closing conditions and regulatory approvals. The expected completion of the transaction is in late 2026. The valuation of the acquired business is below 10 times Enterprise Value / EBITDA. Jefferies Financial Group Inc., RBC Capital Markets, LLC and Rothschild & Co US Inc. acted as financial advisors for Noramco, Inc. Kirkland & Ellis LLP acted as legal advisor for Noramco. The team of Cravath, Swaine & Moore LLP led by G.J. Ligelis Jr., Daniel J. Cerqueira and Ryan J. Wichtowski, Lauren Angelilli, Eric W. Hilfers, David J. Kappos, Carys J. Webb, Margaret T. Segall, Matthew Morreale, Joyce Law, Brian M. Budnick, Crawford Rundlett and Jesús Saracho acted as legal advisor for Siegfried Holding AG.
공시 • Sep 04Siegfried Holding AG to Report Fiscal Year 2025 Results on Feb 20, 2026Siegfried Holding AG announced that they will report fiscal year 2025 results on Feb 20, 2026
공시 • Mar 24Siegfried Holding AG, Annual General Meeting, Apr 10, 2025Siegfried Holding AG, Annual General Meeting, Apr 10, 2025, at 10:00 W. Europe Standard Time.
공시 • Jan 30Siegfried Holding AG to Report First Half, 2025 Results on Aug 21, 2025Siegfried Holding AG announced that they will report first half, 2025 results on Aug 21, 2025
공시 • Aug 22Siegfried Holding AG to Report Fiscal Year 2024 Results on Feb 18, 2025Siegfried Holding AG announced that they will report fiscal year 2024 results on Feb 18, 2025
공시 • Aug 20Siegfried Holding AG to Report First Half, 2024 Results on Aug 22, 2024Siegfried Holding AG announced that they will report first half, 2024 results on Aug 22, 2024
공시 • Jul 02Siegfried Holding AG (SWX:SFZN) completed the acquisition of early-phase CDMO site in Grafton, Wisconsin from Curia Global, Inc.Siegfried Holding AG (SWX:SFZN) agreed to acquire early-phase CDMO site in Grafton, Wisconsin from Curia Global, Inc. on June 12, 2024. The acquisition is financed from existing funds. the transaction is subject to customary closing conditions and is expected to close by July 1, 2024.Siegfried Holding AG (SWX:SFZN) completed the acquisition of early-phase CDMO site in Grafton, Wisconsin from Curia Global, Inc on july 1, 2024. As part of the acquisition, all projects at the Grafton site have been transferred to Siegfried and the Siegfried Acceleration Hub will continue to fulfill all commitments to its existing customers.
공시 • Aug 15+ 1 more updateSiegfried Holding AG to Report Fiscal Year 2023 Results on Feb 20, 2024Siegfried Holding AG announced that they will report fiscal year 2023 results on Feb 20, 2024
공시 • May 18Siegfried Announces Executive ChangesSiegfried announces two changes to its Executive Committee: Irene Wosgien, currently serving as Chief Operating Officer Drug Substances (COO DS), will take over the global responsibility as Chief Human Resources Officer (CHRO) from Arnoud Middel who will leave Siegfried end of June 2023. Henrik Krupper, currently CEO of HCS Group, will join Siegfried to become the new COO DS. Irene Wosgien will take over as CHRO on 1 July 2023 while Arnoud Middel will assist her during the transition and will continue to support key HR projects until the end of the year. Henrik Krupper will assume his role on 1 November 2023 at the latest. Until then and starting on 1 July 2023, Marcel Imwinkelried will lead the DS technical operations organization in parallel to his regular role as Chief Operating Officer Drug Products. Both, Irene Wosgien and Henrik Krupper, will serve as members of Siegfried's Executive Committee. Arnoud Middel joined Siegfried in 2011 and since then has successfully built a professional global HR function which has been instrumental to Siegfried's organizational development and strong growth over the years. After 12 years with the company, he decided to leave Siegfried in order to pursue private ventures and prepare them next chapters of his career. Henrik Krupper (52, German citizen) holds a diploma (Dipl.-Ing.) in mechanical engineering with a specialization in process engineering from the Technical University (RWTH) Aachen (Germany). After completing his studies, he started his career at Th. Goldschmidt AG as site excellence and production manager followed by positions with increasing operational and managerial responsibilities at Evonik Industries AG (formerly Degussa AG), City Solar AG, Q-Cells SE and Soltecture GmbH. In 2012, he joined HCS Group, an international specialty chemicals company based in Germany, as Managing Director and Chief Commercial Officer and was appointed to his current role of Chief Executive Officer of the company in 2019.
공시 • May 06Siegfried Holding AG (SWX:SFZN) acquired 95% stake in DiNAMIQS from DiNAQOR AG.Siegfried Holding AG (SWX:SFZN) acquired 95% stake in DiNAMIQS from DiNAQOR AG on May 4, 2023.Siegfried Holding AG (SWX:SFZN) completed the acquisition of 95% stake in DiNAMIQS from DiNAQOR AG on May 4, 2023.
공시 • Aug 20Siegfried Holding AG to Report Fiscal Year 2022 Results on Feb 22, 2023Siegfried Holding AG announced that they will report fiscal year 2022 results on Feb 22, 2023